<DOC>
	<DOCNO>NCT02085005</DOCNO>
	<brief_summary>Primary Objective : Efficacy : To assess progression-free survival rate 10 month patient maintenance therapy capecitabine plus aflibercept . Secondary Objectives : To evaluate : - Efficacy : Progression Free Survival ( PFS ) - Efficacy : Overall Survival ( OS ) - Efficacy : Objective Response Rate ( ORR ) per Response Evaluation Criteria In Solid Tumors ( RECIST version 1.1 ) criterion - Health related Quality Life ( HRQL ) : EORTC QLQ-C30 score EQ5D-3L - Safety Exploratory Objective : To collect blood tumor sample perform investigation potential biomarker testing .</brief_summary>
	<brief_title>Capecitabine Plus Aflibercept Maintenance Therapy Following Capecitabine Plus Oxaliplatin Plus Aflibercept Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description>Total study duration participant 28 month . This trial conduct country INN designation study molecule `` aflibercept '' term therefore use throughout synopsis . In US , US proper name `` ziv-aflibercept '' .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Inclusion criterion : Age ≥18 year sex Histologically confirm mCRC Unresectable metastatic colorectal cancer . ( Patient resectable metastasis ( liver lung ) eligible . ) Eastern Cooperative Oncology Group ( ECOG ) performance status ≤2 A life expectancy &gt; 3 month At least one measurable lesion accord RECIST ( version 1.1 ) No prior chemotherapy advance disease . Patients prior ( neo ) adjuvant chemotherapy complete 6 month prior metastatic relapse eligible ( adjuvant include chemotherapy resection distant metastasis ) . Adequate hematological profile ( absolute neutrophil count &gt; 1.5 x 109/L , platelet count &gt; 100 x 109/L , hemoglobin &gt; 9 g/dL ) Adequate liver function : AST , ALT &lt; 3.0 x ULN ( &lt; 5 xULN case liver function abnormality due underlie liver metastasis ) ; Alkaline Phosphatase &lt; 3 x ULN ( &lt; 5 x ULN due underlie liver metastasis ) ; Total bilirubin &lt; 1.5 x ULN Serum creatinine &lt; 1.5 x upper limit normal ( ULN ) . If creatinine 1.01.5 x ULN , creatinine clearance calculate accord CKDEPI formula creatinine clearance &lt; 60 mL/min exclude patient Proteinuria &lt; 2+ function Signed patient inform consent begin specific protocol procedure Ability comply protocol requirement Exclusion criterion : Less 4 week prior radiotherapy time inclusion ( le 2 week case palliative RT single bone lesion ) Less 4 week follow major surgery time inclusion surgical wound fully heal whichever come later ( 48 hour case minor surgical procedure wound full heal observe ) Treatment investigational product within 28 day prior inclusion Other prior neoplasm . Adequately treat basal cell squamous cell skin cancer situ cervical cancer cancer patient diseasefree &gt; 5 year allow History brain metastasis ( unless adequately control , i.e . previously irradiate , inactive brain metastasis require active treatment like steroid antiepileptic ) , active seizure disorder , uncontrolled spinal cord compression , carcinomatous meningitis , new evidence brain leptomeningeal disease Any follow within 6 month prior inclusion : myocardial infarction , severe/unstable angina pectoris , coronary/peripheral artery bypass graft , NYHA class III IV congestive heart failure , stroke transient ischemic attack Any follow within 3 month prior inclusion : Grade 34 gastrointestinal bleeding/hemorrhage ( unless due resect tumor ) , treatment resistant peptic ulcer disease , erosive oesophagitis gastritis , infectious inflammatory bowel disease , diverticulitis , pulmonary embolism uncontrolled thromboembolic event Occurrence deep vein thrombosis within 4 week , prior inclusion Any severe acute chronic medical condition , could impair ability patient participate study interfere interpretation study result . Known Acquired immunodeficiency syndrome ( AIDSrelated illness ) know human immunodeficiency virus ( HIV ) disease require antiretroviral treatment Pregnant breastfeed woman . Positive pregnancy test ( serum urine βHCG ) woman reproductive potential Patient reproductive potential ( M/F ) agree use accept effective method contraception study treatment period least 6 month completion study treatment . The definition `` effective method contraception '' base Investigator 's judgment Patient anticoagulant therapy warfarin ( coumarinderivative ) . Anticoagulation low molecular weight heparin ( LWMH ) permit Symptomatic peripheral sensory neuropathy grade ≥ 2 ( NCICTCAE v4.03 ) Inability take oral medication Prior history chronic enteropathy , inflammatory enteropathy , chronic diarrhea , malabsorption syndrome , unresolved bowel obstruction/subobstruction , surgery extensive hemicolectomy , extensive small intestine resection chronic diarrhea . History hypersensitivity fluoropyrimidines known/suspected allergy agent give study excipient study drug Known dihydropyrimidine dehydrogenase deficiency Any contraindication administer oxaliplatin , 5FU , folinic acid capecitabine per package insert drug Uncontrolled hypertension ( define BP &gt; 140/90 mmHg systolic BP &gt; 160 mmHg diastolic BP &lt; 90 mmHg , least 2 repeated determination separate day , upon clinical judgment ) within 3 month prior study inclusion Evidence clinically significant bleed diathesis underlie coagulopathy ( e.g . INR &gt; 1.5 without vitamine K antagonist therapy ) , nonhealing wound History hypersensitivity Aflibercept ( case prior administration indication cancer , i.e . ophthalmic indication ) The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>